Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirarubicin Instillation for Bladder Recurrence Prevention in UTUC
NCT03030157Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of pirarubicin in bladder cancer, sponsored by Renji Hospital. Status: unknown.
02
Drugs
pirarubicin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03030157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030157.